Novo Nordisk A/S
(NYSE : NVO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.46%168.100.7%$1318.70m
PFEPfizer Inc. 0.65%39.610.9%$1301.66m
MRKMerck & Co., Inc. 0.65%77.960.7%$905.52m
BMYBristol-Myers Squibb Co. 0.33%64.471.0%$717.41m
ABBVAbbVie, Inc. 0.17%115.081.9%$714.96m
LLYEli Lilly & Co. -0.92%192.961.1%$575.86m
AZNAstraZeneca Plc 0.74%54.501.2%$541.26m
BTXBrooklyn ImmunoTherapeutics, Inc. -8.33%28.0512.8%$320.94m
GSKGlaxoSmithKline Plc 0.21%38.270.2%$192.78m
NVSNovartis AG 0.07%87.470.2%$167.85m
VTRSViatris, Inc. 3.60%15.690.0%$156.87m
CVACCureVac NV -4.37%93.690.0%$138.35m
SNYSanofi -0.40%51.740.2%$69.69m
NVONovo Nordisk A/S 1.66%77.900.1%$65.72m
MNMDMind Medicine (MindMed), Inc. -4.87%2.930.0%$60.73m

Company Profile

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.